Preview

Онкогематология

Расширенный поиск

Практические аспекты терапии хронического миелолейкоза в хронической фазе

https://doi.org/10.17650/1818-8346-2012-7-3-8-16

Полный текст:

Аннотация

.

Об авторах

А. Г. Туркина
ФГБУ «Гематологический научный центр» Минздрава России
Россия


Р. Хельманна
Гейдельбергский университет
Россия


Т. И. Поспелова
ГБОУ ВПО «Новосибирский государственный медицинский университет» Минздрава России
Россия


Т. И. Виноградова
ФГБУ «Гематологический научный центр» Минздрава России
Россия


Т. И. Ионова
Межнациональный центр исследования качества жизни
Россия


Список литературы

1. Marin D., Bazeos A., Mahon F‑X. et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381−8.

2. Baccarani M., Cortes J., Pane F. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009;27:6041−51.

3. Shah N.P., Kantarjian H.M., Kim D‑W. et al. Six‑year follow‑up of patients with imatinib-resistant or -intolerant chronicphase chronic myeloid leukemia (CML‑CP) receiving dasatinib. ASCO 2012, abstract 6506.

4. Kantarjian H.M., Giles F.J., Bhalla K.N. et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24‑month follow‑up results. Blood 2011; 117(4):1141−5.

5. Cortes J.E., Kantarjian H.M., Brummendorf T.H. et al. Safety and efficacy of bosutinib (SKI‑606) in chronic phase Philadelphia chromosome — positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118(17):4567−76.

6. Porkka K., Khoury H.J., Paquette R.L. et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116:377−86.

7. Jabbour E., Deininger M. and Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011; 25(2):201−10.

8. Masiello D., Gorospe G. and Yang A.S. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009;2:46.

9. Le Coutre P., Rea D., Abruzzese E. et al. Severe peripheral arterial disease during nilotinib therapy. JNCI 2011;103(17):1347−8.

10. Giles F.J., Mauro M.J., Hong F. et al. Retrospective Cohort analysis of Peripheral Arterial Occlusive Disease (PAOD) events in patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML‑CP). Blood (ASH Annual Meeting Abstracts), Nov 2011;118:2757.

11. Montani, D., Bergot E., Guenther S. et al. Pulmonary Arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128−37.

12. Cortes J.E., Kim D‑W., Pinilla‑Ibarz J. et al. Initial findings from the PACE Trial: A pivotal phase 2 study of ponatinib in patients with CML and Ph+ all resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Blood (ASH Annual Meeting Abstracts), Nov 2011;118:109.

13. Druker B.J., Guilhot F., O’Brien S.G. et al. Five‑year follow‑up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408−17.

14. Saglio G., Kim D‑W., Issaragrisil S. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251−9.

15. De Lavallade H., Apperley J.F., Khorashad J.S. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to‑treat analysis. J Clin Oncol 2008;26:3358−63.

16. Hochhaus A., Shah N.P., Cortes J.E. et al. Dasatinib vs. imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: DASISION 3‑year follow‑up. ASCO 2012, abstract 6504.

17. Kantarjian H.P., Hochhaus A., Saglio G. et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosomepositiva, chronic myeloid leukemia: 24‑month minimum follow‑up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841−51.

18. Quintás‑Cardama A. and Cortes J. Molecular biology of bcr‑abl1‑positive chronic myeloid leukemia. Blood 2009 Feb 19;113(8):1619−30.

19. Dierov J., Sanchez P.V., Burke B.A. et al. BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia 2009 Feb;23(2):279−86.

20. Skorski T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leuk Lymphoma 2008 Apr;49(4):610−4.

21. Neverova L., Zakharova A., Udovichenko A. et al. Additional chromosome aberrations in chronic myeloid leukemia patients undergoing tyrosine kinase inhibitors therapy. EHA 2010, poster 0822.


Для цитирования:


Туркина А.Г., Хельманна Р., Поспелова Т.И., Виноградова Т.И., Ионова Т.И. Практические аспекты терапии хронического миелолейкоза в хронической фазе. Онкогематология. 2012;7(3):8-16. https://doi.org/10.17650/1818-8346-2012-7-3-8-16

For citation:


., ., ., ., . . Oncohematology. 2012;7(3):8-16. (In Russ.) https://doi.org/10.17650/1818-8346-2012-7-3-8-16

Просмотров: 406


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1818-8346 (Print)
ISSN 2413-4023 (Online)